RXDX vs. ZLAB, ROIV, PEN, TFX, HSIC, CRL, QGEN, BIO, RGEN, and DVA
Should you be buying Prometheus Biosciences stock or one of its competitors? The main competitors of Prometheus Biosciences include Zai Lab (ZLAB), Roivant Sciences (ROIV), Penumbra (PEN), Teleflex (TFX), Henry Schein (HSIC), Charles River Laboratories International (CRL), Qiagen (QGEN), Bio-Rad Laboratories (BIO), Repligen (RGEN), and DaVita (DVA). These companies are all part of the "medical" sector.
Zai Lab (NASDAQ:ZLAB) and Prometheus Biosciences (NASDAQ:RXDX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
Zai Lab has a net margin of -156.07% compared to Zai Lab's net margin of -3,768.76%. Zai Lab's return on equity of -33.50% beat Prometheus Biosciences' return on equity.
Prometheus Biosciences received 110 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 70.64% of users gave Prometheus Biosciences an outperform vote while only 62.50% of users gave Zai Lab an outperform vote.
Prometheus Biosciences has lower revenue, but higher earnings than Zai Lab. Prometheus Biosciences is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.
43.7% of Zai Lab shares are held by institutional investors. Comparatively, 92.7% of Prometheus Biosciences shares are held by institutional investors. 5.2% of Zai Lab shares are held by insiders. Comparatively, 3.4% of Prometheus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Zai Lab presently has a consensus price target of $83.10, suggesting a potential upside of 259.74%. Prometheus Biosciences has a consensus price target of $162.70, suggesting a potential downside of 18.62%. Given Prometheus Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Prometheus Biosciences.
In the previous week, Zai Lab had 1 more articles in the media than Prometheus Biosciences. MarketBeat recorded 1 mentions for Zai Lab and 0 mentions for Prometheus Biosciences. Prometheus Biosciences' average media sentiment score of 1.87 beat Zai Lab's score of 0.77 indicating that Zai Lab is being referred to more favorably in the media.
Zai Lab has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Prometheus Biosciences has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500.
Summary
Zai Lab beats Prometheus Biosciences on 9 of the 17 factors compared between the two stocks.
Get Prometheus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Prometheus Biosciences Competitors List
Related Companies and Tools